Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

Journal of Medical Virology

Volumn 81, Issue 12, 2009, Pages 2029-2035

  Legrand Abravanel, Florence ^a   Colson, Philippe ^b   Leguillou Guillemette, Hélène ^c   Alric, Laurent ^a   Ravaux, Isabelle ^b   Lunel Fabiani, Françoise ^c   Bouviers Alias, Magali ^d   Trimoulet, Pascale ^e   Chaix, Marie Laure ^f   Hézode, Christophe ^d   Foucher, Juliette ^e   Fontaine, Hélène ^g   Roque Afonso, Anne Marie ^h   Gassin, Michèle ⁱ   Schvoerer, Evelyne ^j   Gaudy, Catherine ^k   Roche, Bruno ^h   Doffoël, Michel ^j   D'Alteroche, Louis ^k   Vallet, Sophie ^l   Baazia, Yazid ^m   Pozzetto, Bruno ⁿ   Thibault, Vincent ^o   Nousbaum, Jean Baptiste ^l   Roulot, Dominique ^p   Coppere, Henry ⁿ   Poinard, Thierry ^o   Payan, Christopher ^l   Izopet, Jacques ^a   more..

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d Centre Hospitalier Universitaire   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g Centre Hospitalier Universitaire Avicenne ^*  (France)

^h Section of Radiology   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l BREST UNIVERSITY HOSPITAL   (France)

^m AVICENNE HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^p Jean Verdier University   (France)

more..

Author keywords

HCV subtype; Interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 70350580914     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21583     Document Type: Article

References (36)

1. Bonny C, Fontaine H, Poynard T, Hezode C, Larrey D, Marcellin P, Bourliere M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. 2006. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 24:593-600.
2. Camma C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, Mangia A, Andriulli A, Puoti M, Spadaro A, Freni M, Di Marco V, Cino L, Saracco G, Chiesa A, Crosignani A, Caporaso N, Morisco F, Rumi MG, Craxi A. 2002. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: A meta-analysis of individual patient data. Gut 51:864-869. (Pubitemid 35408610)
3. Cantaloube JF, Laperche S, Gallian P, Bouchardeau F, de Lamballerie X, de Micco P. 2006. Analysis of the 50 noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France. J Clin Microbiol 44:2051-2056. (Pubitemid 43902152)
4. Chen Z, Weck KE. 2002. Hepatitis C virus genotyping: Interrogation of the 5′ untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 40:3127-3134. (Pubitemid 34977418)
5. Dienstag JL, McHutchison J. 2006. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 130:231-264.
6. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. 2006. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (Baltimore, MD) 44:1675-1684. (Pubitemid 44953672)
7. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Loschenberger K, Formann E, Staufer K, Steindl-Munda P. 2008. Peginterferon alfa- 2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135:451-458.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
9. Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, Yuen MF. 2008. Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin. J Infect Dis 198:808-812.
10. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355. (Pubitemid 38268915)
11. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B. 2004. Peginterferon alfa-2b plus ribaririn for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 99:1733-1737. (Pubitemid 39237501)
12. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. 2003. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1. J Infect Dis 187:1071-1074. (Pubitemid 36399349)
13. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. 2005. Peginterferon (alpha)-2b and ribavirin therapy in chronic hepatitisq C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 54:858-866. (Pubitemid 40732106)
14. Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD. 2005. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 43:243-249. (Pubitemid 40956876)
15. Laperche S, Lunel F, Izopet J, Alain S, Deny P, Duverlie G, Gaudy C, Pawlotsky JM, Plantier JC, Pozzetto B, Thibault V, Tosetti F, Lefrere JJ. 2005. Comparison of hepatitis C virus NS5b and 5′ noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 43:733-739. (Pubitemid 40256027)
16. Legrand-Abravanel F, Sandres-Saune K, Barange K, Alric L, Moreau J, Desmorat P, Vinel JP, Izopet J. 2004. Hepatitis C virus genotype 5: Epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 189:1397-1400. (Pubitemid 38543588)
17. Legrand-Abravanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L, Izopet J. 2005. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 77:66-69. (Pubitemid 41076478)
18. Lindenbach BD, Rice CM. 2005. Unravelling hepatitis C virus replication from genome to function. Nature 436:933-938. (Pubitemid 41191668)
19. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965. (Pubitemid 32913521)
20. Martin-Carbonero L, Puoti M, Garcia-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Marino A, Gonzalez M, Nunez M, Soriano V. 2008. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. J Viral Hepat 15:710-715.
21. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
22. Nicot F, Legrand-Abravanel F, Lafont T, Dubois M, Saune K, Pasquier C, Chatelut E, Izopet J. 2008. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 80:1523-1529.
23. Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S, Colucci G, Smedile A, Ghisetti V. 2008. Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol 80:254-260.
24. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432. (Pubitemid 28510876)
25. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourliere M, Zarski JP, Roudot-Thoraval F. 2007. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 14:460-467. (Pubitemid 46944469)
26. Sandres-Saune K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. 2003. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 109:187-193. (Pubitemid 36507107)
27. Sarrazin C, Gartner BC, Sizmann D, Babiel R, Mihm U, Hofmann WP, von Wagner M, Zeuzem S. 2006. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 44:729-737.
28. Serpaffi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, Viard JP, Piketty C, Rouveix E, Rouzioux C, Weiss L, Pol S. 2006. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1 infected men and inefficacy of early antiviral therapy. AIDS 20:233-240.
29. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS. 2006. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 55:1631-1638. (Pubitemid 44629215)
30. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (Baltimore, MD) 42:962-973. (Pubitemid 41401136)
31. Sulkowski M, Lawitz E, Shiffman ML, Muir AJ, Galler G, McCone J, Nyberg LM, Lee W, Ghalib R, Schiff E, Galati J, Bacon B, Davis M, Mukhopadhyay P, Noviello v, Pedicone L, Albrecht J, McHutchison J. 2008. Final results of the IDEAL (Individualised dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIB study. J Hepatol 48:S370-S371.
32. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. 2008. Differences between two real-time PCR based assays (RealTime HCV, COBAS AmpliPrep/COBAS TaqMan) and one signal amplification assay (VERSANT HCV RNA 3.0) for HCV RNA detection and quantification. J Clin Microbiol 16:3880-3891.
33. Vispo E, Barreiro P, Rodriguez-Novoa S, Morello J, Labarga P, Martin- Carbonero L, Maida I, Garcia-Gasco P, Soriano V. 2008. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antivir Ther 13:511-517. (Pubitemid 352016713)
34. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. 2008. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology (Baltimore, MD) 47:1884-1893. (Pubitemid 351945556)
35. Zeuzem S. 2004. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? Ann Intern Med 140:370-381.
36. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J. 2006. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44:97-103. (Pubitemid 41772522)